<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-02-15</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-02-15</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>43</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
PKM2ä¹³é…¸åŒ–åœ¨ç»“ç›´è‚ ç™Œè¡€ç®¡ç”Ÿæˆæ¨¡æ‹Ÿå’Œè€è¯æœºåˆ¶ä¸­èµ·å…³é”®ä½œç”¨ï¼Œé€šè¿‡è°ƒæ§FOSL1è¶…çº§å¢å¼ºå­å½¢æˆã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒè°ƒæ§ï¼šé€šè¿‡è¡¨è§‚é—ä¼ å­¦å¼€å…³è°ƒèŠ‚è¡€ç®¡è¡¨å‹ï¼Œå¢å¼ºæŠ—è‚¿ç˜¤å…ç–«ï¼›Tç»†èƒè€—ç«­è¿›åŒ–ä¸æ·‹å·´ç»“å¾®ç¯å¢ƒã€‚<br />
- ç™Œç—‡è€è¯æœºåˆ¶ï¼šPKM2ä¹³é…¸åŒ–ä»‹å¯¼çš„è¡€ç®¡ç”Ÿæˆæ¨¡æ‹Ÿï¼›SMARCA4è°ƒæ§PROX1å’ŒH3K27ä¹™é…°åŒ–æŠµæŠ—å‰åˆ—è…ºç™Œæ©æ‰å¢èƒºã€‚<br />
- è‚ é“å…ç–«ç¨³æ€ï¼šæ ‘çªçŠ¶ç»†èƒäº§ç”ŸIFN-Î»ï¼›Caspases 3/7è°ƒæ§è‚ é“ç‚ç—‡å’Œç»†èƒç„¦äº¡ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ç»“åˆå•ç»†èƒRNA-seqï¼ˆscRNA-seqï¼‰ã€å…¨åŸºå› ç»„ç»“åˆ/å æœ‰ç‡æµ‹åºï¼ˆATAC-seq, ChIP-seq, CUT&amp;Tagï¼‰ç­‰å¤šç»„å­¦æŠ€æœ¯ï¼Œæ·±å…¥è§£æç»†èƒå¼‚è´¨æ€§å’Œè°ƒæ§æœºåˆ¶ã€‚<br />
- å»ºç«‹ä½“å¤–3Dç»†èƒåŸ¹å…»æ¨¡å‹ï¼Œæ¨¡æ‹Ÿä¹³è…ºç™Œç»†èƒæ°§åŒ–ä»£è°¢ï¼Œä¸ºç ”ç©¶æä¾›æ–°å¹³å°ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
é¦–æ¬¡åˆ©ç”¨Nanoporeæµ‹åºæŠ€æœ¯ï¼Œå®ç°å¯¹å®Œæ•´æ°¨é…°åŒ–tRNAï¼ˆaa tRNAï¼‰çš„ç›´æ¥æµ‹åºï¼Œä»è€Œé‰´å®šä¸ªä½“tRNAä¸Šçš„æ°¨åŸºé…¸é™„ç€æƒ…å†µã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- æ­ç¤ºtRNAä¿®é¥°å¦‚ä½•å½±å“å…¶ç¨³å®šæ€§å’Œæ°¨é…°åŒ–æ•ˆç‡ã€‚<br />
- æ¢ç´¢ä¸åŒæ°¨åŸºé…¸åœ¨tRNAä¸Šçš„åˆ†å¸ƒåŠä¸ç¿»è¯‘è¿‡ç¨‹çš„å…³è”ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å¼€å‘äº†æ–°å‹çš„aa tRNAæµ‹åºï¼ˆaa tRNA seqï¼‰æ–¹æ³•ï¼Œç»“åˆNanoporeé•¿è¯»é•¿å’Œç›´æ¥æ£€æµ‹èƒ½åŠ›ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (42æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE319479 è¡€ç®¡è¡¨å‹ä¸­çš„è¡¨è§‚é—ä¼ è½¬æ¢å¢å¼ºæŠ—è‚¿ç˜¤å…ç–«åŠ› [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€scRNAã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Dae Joong Kim ; Mitchell McGinty ; Swetha Anandh ; Caroline Riedstra ; Yuvraj Sethi ; Melanie Rutkowski ; Andrew DudleySeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe abnormal tumor vasculature can present a barrier to the infiltration of anti-tumor immune cells, which impairs immune surveillance and response to immunotherapy. Here, we show that targeting the epigenetic factor DNA methyltransferase 1 in endothelial cells (ECs) results in reduced angiogenesis while imparting profound changes to the tumor immune microenvironment (TIME), including increased proportions of CD4+ memory T-cells and NK cells. Depleting CD4+ T-cells, or blocking lymphocyte egress from the lymph nodes with FTY720, rescues tumor growth in mice with conditional deletion of Dnmt1 in ECs (Dnmt1iECKO) and dramatically shortens overall survival, whereas NK cells are dispensable. Tumors implanted in Dnmt1iECKO mice show reduced vascular branching, elevated expression of Vcam1, increased vessel-associated T-cells, and a shift in vascular specification including increased proportions of immune-permissive post-capillary venules (PCVs) and interferon-stimulated ECs (IFN_x0002_ECs). Deleting Dnmt1 in EC cultures strikingly potentiates responses to combinations of IFNg and TNFa and, notably, up-regulates important T-cell co-stimulatory molecules for memory CD4+ T-cells, including Icosl, Cd40, and Tnfsf4. Finally, immune checkpoint blockade (ICB) administered to Dnmt1iECKO mice with experimental melanoma lung metastasis reduces tumor burden, with some mice showing tumor eradication. Our findings identify endothelial Dnmt1 as a key regulator of vascular-mediated anti-tumor immunity, providing a rationale for integrating epigenetic modulation of the vasculature with cancer immunotherapy regimens.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319479" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE318850 æ·‹å·´ç»“-è‚¿ç˜¤è€—ç«­Tç»†èƒå…‹éš†æ¼”åŒ–çš„æ—¶ç©ºå›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€lymphã€T cellã€regex:lymph(o|atic)?<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yang Zhang ; Haiquan ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCurrent surgical guidelines overlook preserving uninvolved lymph nodes (uiLNs) in non-small cell lung cancer, principally stemming from an underappreciation of their critical role in anti-tumor immunity. Here, we discovered a significant immunosuppressive microenvironment in metastatic lymph nodes. In contrast, CD200+ progenitor exhausted T cells (Tpex) markedly expanded within uiLNs following immunotherapy. Effective clonal sharing of exhausted T cells between uiLNs and tumors correlated strongly with complete pathological response. Previously unrecognized tumor-resident C1QA+ dendritic cells secreted CXCL9, facilitating T cell recruitment, whereas fibroblast-enriched neighborhoods in non-responders created immunosuppressive barriers hindering CXCL9 diffusion and CD200+ Tpex migration. Finally, we confirmed that tumor-reactive Tex clones from uiLNs could persist systemically and identified two neoantigen peptides as direct targets of these tumor-reactive Tex cells. Our study unprecedentedly elucidates the spatiotemporal dynamics of immunotherapy-responsive T cell subsets in LN-tumor axis and provides compelling evidence to support selective LN dissection strategies to preserve uiLNs.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318850" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE319480 è¡€ç®¡è¡¨å‹ä¸­çš„è¡¨è§‚é—ä¼ è½¬æ¢å¢å¼ºæŠ—è‚¿ç˜¤å…ç–«åŠ› [bulkRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Dae Joong Kim ; Mitchell McGinty ; Swetha Anandh ; Caroline Riedstra ; Yuvraj Sethi ; Melanie Rutkowski ; Andrew DudleySeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe abnormal tumor vasculature can present a barrier to the infiltration of anti-tumor immune cells, which impairs immune surveillance and response to immunotherapy. Here, we show that targeting the epigenetic factor DNA methyltransferase 1 in endothelial cells (ECs) results in reduced angiogenesis while imparting profound changes to the tumor immune microenvironment (TIME), including increased proportions of CD4+ memory T-cells and NK cells. Depleting CD4+ T-cells, or blocking lymphocyte egress from the lymph nodes with FTY720, rescues tumor growth in mice with conditional deletion of Dnmt1 in ECs (Dnmt1iECKO) and dramatically shortens overall survival, whereas NK cells are dispensable. Tumors implanted in Dnmt1iECKO mice show reduced vascular branching, elevated expression of Vcam1, increased vessel-associated T-cells, and a shift in vascular specification including increased proportions of immune-permissive post-capillary venules (PCVs) and interferon-stimulated ECs (IFN_x0002_ECs). Deleting Dnmt1 in EC cultures strikingly potentiates responses to combinations of IFNg and TNFa and, notably, up-regulates important T-cell co-stimulatory molecules for memory CD4+ T-cells, including Icosl, Cd40, and Tnfsf4. Finally, immune checkpoint blockade (ICB) administered to Dnmt1iECKO mice with experimental melanoma lung metastasis reduces tumor burden, with some mice showing tumor eradication. Our findings identify endothelial Dnmt1 as a key regulator of vascular-mediated anti-tumor immunity, providing a rationale for integrating epigenetic modulation of the vasculature with cancer immunotherapy regimens.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319480" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE307937 PKM2 ä¹³é…¸åŒ–ä¿ƒè¿›ç»“ç›´è‚ ç™Œè¡€ç®¡ç”Ÿæˆæ‹Ÿæ€å’Œå¯¹è´ä¼å•æŠ—æ²»ç–—çš„è€è¯æ€§ï¼Œé€šè¿‡ä¿ƒè¿› FOSL1 è¶…çº§å¢å¼ºå­å½¢æˆ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Weihao Li ; Jianhong Peng ; Jiahua He ; Zhizhong Pan ; Chi Zhou ; Junzhong LinSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDespite the clinical utility of bevacizumab in advanced colorectal cancer (CRC), resistance remains a major challenge. Here, we unveiled a lactate-mediated mechanism driving vasculogenic mimicry (VM) and bevacizumab resistance through PKM2 lactylation. PKM2 lactylation at K206 by AARS1 promoted PKM2 nuclear translocation and interaction with FOSL1. PKM2 binding facilitated FOSL1-dependent super-enhancer formation and target gene transcription, which contributed to CRC cell VM. Genetic or pharmacological inhibition of PKM2 lactylation disrupted VM and synergized with bevacizumab in patient-derived pre-clinical models, significantly improving therapeutic efficacy. Together, this study reveals lactylation as a metabolic switch linking cancer glycolytic reprogramming to transcriptional rewiring and proposes targeting PKM2 lactylation to enhance the anti-tumor activity of bevacizumab in CRC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307937" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE307935 PKM2 ä¹³é…¸åŒ–ä¿ƒè¿›ç»“ç›´è‚ ç™Œè¡€ç®¡ç”Ÿæˆæ‹Ÿæ€å’Œå¯¹è´ä¼å•æŠ—æ²»ç–—çš„è€è¯æ€§ï¼Œå…¶æœºåˆ¶æ˜¯é€šè¿‡ä¿ƒè¿› FOSL1 è¶…çº§å¢å¼ºå­çš„å½¢æˆ [ATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€ATAC-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Weihao Li ; Jianhong Peng ; Jiahua He ; Zhizhong Pan ; Chi Zhou ; Junzhong LinSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensDespite the clinical utility of bevacizumab in advanced colorectal cancer (CRC), resistance remains a major challenge. Here, we unveiled a lactate-mediated mechanism driving vasculogenic mimicry (VM) and bevacizumab resistance through PKM2 lactylation. PKM2 lactylation at K206 by AARS1 promoted PKM2 nuclear translocation and interaction with FOSL1. PKM2 binding facilitated FOSL1-dependent super-enhancer formation and target gene transcription, which contributed to CRC cell VM. Genetic or pharmacological inhibition of PKM2 lactylation disrupted VM and synergized with bevacizumab in patient-derived pre-clinical models, significantly improving therapeutic efficacy. Together, this study reveals lactylation as a metabolic switch linking cancer glycolytic reprogramming to transcriptional rewiring and proposes targeting PKM2 lactylation to enhance the anti-tumor activity of bevacizumab in CRC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307935" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE304885 è‚ é“æµ†ç»†èƒæ ·æ ‘çªçŠ¶ç»†èƒä¼˜å…ˆäº§ç”Ÿå¹²æ‰°ç´ Î» [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šscRNAã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : David A Constant ; Timothy J NiceSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusThe healthy intestine mounts immune responses to microbiota to maintain homeostasis, which includes basal production of interferon cytokines. Previous work showed that Type III Interferon (IFN-Î») stimulates localized pockets of interferon-stimulated genes (ISGs) in the adult mouse intestinal epithelium at homeostasis that provide preemptive protection from viral pathogens. Here, we demonstrate that a major source of homeostatic IFN-Î» production in the intestine is a population of epithelium-associated plasmacytoid dendritic cells (pDC). These pDC are recruited to the intestine by bacterial microbiota colonization, and pDC depletion or bone marrow reconstitution with IFN-Î»-deficient pDC results in reduced homeostatic ISGs in the intestinal epithelium. Notably, intestinal pDC preferentially produce IFN-Î» over Type I IFNs whereas splenic pDC produce more Type I IFNs. Comparison of splenic and intestinal pDC reveal tissue-specific changes in gene expression and genomic accessibility, including evidence of response to transforming growth factor beta (TGF-Î²) in the intestine. Isolated gut pDC produce more IFN-Î» that splenic pDC upon stimulation, and pre-treatment of a human pDC cell line with TGF-Î² results in enhanced production of IFN-Î» upon stimulation. This study implicates pDC as important sources of homeostatic IFN-Î» in the intestine and defines the role of barrier cytokine TGF-Î² in regulating IFN types produced by pDC upon stimulation. Reprogramming of recruited pDC by tissue cytokines may have important implications for balancing effective antimicrobial responses with damaging inflammation at barrier tissues.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304885" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE304884 è‚ é“æµ†ç»†èƒæ ·æ ‘çªçŠ¶ç»†èƒä¼˜å…ˆäº§ç”Ÿå¹²æ‰°ç´ Î» [ATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šATAC-seqã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : David A Constant ; Timothy J NiceSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusThe healthy intestine mounts immune responses to microbiota to maintain homeostasis, which includes basal production of interferon cytokines. Previous work showed that Type III Interferon (IFN-Î») stimulates localized pockets of interferon-stimulated genes (ISGs) in the adult mouse intestinal epithelium at homeostasis that provide preemptive protection from viral pathogens. Here, we demonstrate that a major source of homeostatic IFN-Î» production in the intestine is a population of epithelium-associated plasmacytoid dendritic cells (pDC). These pDC are recruited to the intestine by bacterial microbiota colonization, and pDC depletion or bone marrow reconstitution with IFN-Î»-deficient pDC results in reduced homeostatic ISGs in the intestinal epithelium. Notably, intestinal pDC preferentially produce IFN-Î» over Type I IFNs whereas splenic pDC produce more Type I IFNs. Comparison of splenic and intestinal pDC reveal tissue-specific changes in gene expression and genomic accessibility, including evidence of response to transforming growth factor beta (TGF-Î²) in the intestine. Isolated gut pDC produce more IFN-Î» that splenic pDC upon stimulation, and pre-treatment of a human pDC cell line with TGF-Î² results in enhanced production of IFN-Î» upon stimulation. This study implicates pDC as important sources of homeostatic IFN-Î» in the intestine and defines the role of barrier cytokine TGF-Î² in regulating IFN types produced by pDC upon stimulation. Reprogramming of recruited pDC by tissue cytokines may have important implications for balancing effective antimicrobial responses with damaging inflammation at barrier tissues.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304884" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE297859 åŠèƒ±å¤©å†¬é…¶ 3 å’Œ 7 é€šè¿‡è°ƒèŠ‚å¹²ç»†èƒåŠŸèƒ½å’Œ gsdmd ä»‹å¯¼çš„ç»†èƒç„¦äº¡æ¥é™åˆ¶è‚ é“ç‚ç—‡</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šinflammationã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xie Wei ; Verstraeten Bruno ; Vandenabeele PeterSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAberrant intestinal epithelial cell (IEC) death is a hallmark of inflammatory bowel disease (IBD), observed in patient samples and animal models of colitis. While multiple cell death pathways contribute to disease pathogenesis, the dominant modalities and their regulatory mechanisms in IBD remain poorly defined. In this study, we demonstrate that mice with intestinal epithelial cell-specific deletion of caspase-3 and -7 (Casp3/7 Tg) exhibit exacerbated colitis, increased mortality, and impaired epithelial regeneration, phenotypes not observed in other cell death-related knockout models. These findings highlight a previously unrecognized protective role of caspase-3/7 in controlling inflammation and tissue regeneration following intestinal injury. Mechanistically, caspase-3/7 deficiency negatively affects intestinal stem cell proliferation and promotes GSDMD-dependent pyroptosis, compromising barrier integrity and return to steady state conditions. Together, our results identify caspase-3/7 as key regulators of epithelial integrity and inflammation and suggest their modulation as a promising therapeutic strategy in IBD and colorectal cancer.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297859" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE240483 NAD+ æ§åˆ¶å¿ƒè„è¡°è€è¿‡ç¨‹ä¸­çš„æ˜¼å¤œèŠ‚å¾‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šagingã€cardiac<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Bryce J Carpenter ; Margaux Lecacheur ; Yannick N Mangold ; Kai Cui ; Stefan GÃ¼nther ; Marit W Vermunt ; Pieterjan DierickxSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusDisruption of the circadian clock as well as reduced NAD+ levels are both hallmarks of aging. While circadian rhythms and NAD+ metabolism have been linked in heart disease, their relationship during cardiac aging is less clear. Here, we show that aging leads to disruption of diurnal gene expression in the heart. Long-term supplementation with the NAD+ precursor nicotinamide riboside (NR) boosts NAD+ levels, reprograms the diurnal transcriptome, and reverses naturally occurring cardiac enlargement in aged female mice. In addition, drastic reduction of NAD+ levels in CMs impairs PER2::luc oscillations, which is rescued by NR supplementation. Finally, we demonstrate that changes to the cardiac transcriptome due to NR treatment partially depend on the activity of SIRT1. These findings reveal an essential role for NAD+ in regulation of the cardiac circadian clock upon aging, which opens up new avenues to counteract age-related cardiac disorders.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE240483" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE309277 ä¸€ç§ç®€å•çš„æ¶²æ€3Dç»†èƒåŸ¹å…»æ¨¡å‹æ¨¡æ‹Ÿäº†ä¸è‚ºè½¬ç§»ç›¸å…³çš„ä¸Šçš®ä¹³è…ºç™Œç»†èƒçš„æ°§åŒ–çº¿ç²’ä½“ä»£è°¢</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Balamurugan Kuppusamy ; Esta SterneckSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThree-dimensional (3D) cell culture systems have emerged as powerful tools to model tumor biology ex vivo. However, the diverse array of 3D culture methods available presents challenges in selecting the most appropriate model for specific research questions. This study provides a comparative analysis of breast cancer cells (SUM149, IBC-3, MDA-MB-468) in the mammosphere culture (SphC) model or an â€œemboliâ€ culture (EmC) model, which enrich for cancer stem cells and epithelial features, respectively. The EmC model, designed originally for inflammatory breast cancer, is characterized by media viscosity and mechanical rocking of the culture vessel. Notably, cells in EmC showed a distinct and durable reduction in cell proliferation while demonstrating increased capacity to establish experimental lung metastases. Quantitative analysis of electron microscopy images suggested that cells in EmC acquire nuclear and mitochondrial features that resemble those of tumor tissue. Proteomics, single-cell transcriptomics, and metabolic flux analyses showed that cells in EmC and SphC favor mitochondrial oxidative metabolism (OXPHOS) and glycolysis, respectively. EmC rendered cells hypersensitive to OXPHOS inhibition, yet more resistant to oxidative stress. Several genes associated with lung metastasis, including ID1, were specifically enriched in EmC. Given the increasingly recognized role of OXPHOS in cancer cell survival during dissemination and as established metastases, we propose that the EmC paradigm is a suitable ex vivo model to study signaling pathways relevant for tumor tissue and to assess drug sensitivities and resistance mechanisms of metastatic breast cancer cells ex vivo<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309277" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 32 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>å®Œæ•´æ°¨é…°åŒ–tRNAçš„çº³ç±³å­”æµ‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šUsing RNA sequencing with nanopore technology, researchers developed aa tRNA seq to identify amino acids attached to individual tRNAs, revealing how modifications influence tRNA stability and charging fidelity...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/nanopore-sequencing-of-intact-aminoacylated-trnas/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>12</td>
</tr>
<tr>
<td>immune</td>
<td>9</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>5</td>
</tr>
<tr>
<td>regex:intestin(e</td>
<td>al)</td>
</tr>
<tr>
<td>scRNA</td>
<td>4</td>
</tr>
<tr>
<td>resistance</td>
<td>4</td>
</tr>
<tr>
<td>tumor</td>
<td>3</td>
</tr>
<tr>
<td>immunity</td>
<td>2</td>
</tr>
<tr>
<td>epigenetic</td>
<td>2</td>
</tr>
<tr>
<td>single-cell</td>
<td>2</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>2</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
<tr>
<td>metabolism</td>
<td>2</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>2</td>
</tr>
<tr>
<td>genome</td>
<td>2</td>
</tr>
<tr>
<td>sequencing</td>
<td>1</td>
</tr>
<tr>
<td>inflammation</td>
<td>1</td>
</tr>
<tr>
<td>aging</td>
<td>1</td>
</tr>
<tr>
<td>cardiac</td>
<td>1</td>
</tr>
<tr>
<td>RNAseq</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (32æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305432" target="_blank" rel="noopener noreferrer">GSE305432 FOXA1/FOXM1 ChIP-seq åœ¨ giredestrant è€è¯çš„ ER+ ä¹³è…ºç™Œç»†èƒç³»ä¸­çš„åº”ç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303505" target="_blank" rel="noopener noreferrer">GSE303505 ä¸Šçš®-é—´è´¨è½¬åŒ–ä¸ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…ç–«ç»„æˆå’Œç»†èƒæ¯’æ€§åŠŸèƒ½æ”¹å˜ç›¸å…³</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295127" target="_blank" rel="noopener noreferrer">GSE295127 å¯¹è€å‰ç‘åœ°å¸ä»–æ±€çš„ ER+ ä¹³è…ºç™Œç»†èƒç³»è¿›è¡Œ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304155" target="_blank" rel="noopener noreferrer">GSE304155 HE4 é€šè¿‡ IFN-Î³R-STAT3 è½´ä¸Šè°ƒå·¨å™¬ç»†èƒä¸Šçš„ PD-L1 è¡¨è¾¾æ¥è°ƒèŠ‚æŠ—ç™Œå…ç–«é€ƒé€¸ [LLC è‚¿ç˜¤ï¼ŒscRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298587" target="_blank" rel="noopener noreferrer">GSE298587 HE4 é€šè¿‡ IFN-Î³R-STAT3 è½´ä¸Šè°ƒå·¨å™¬ç»†èƒä¸Šçš„ PD-L1 è¡¨è¾¾æ¥è°ƒèŠ‚æŠ—ç™Œå…ç–«é€ƒé€¸ [RNA-Seq - ç»†èƒç³»]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319496" target="_blank" rel="noopener noreferrer">GSE319496 è½¬ç§»æ€§è‚¾ç»†èƒç™Œæ‚£è€…æ¥å—çº³æ­¦åˆ©å°¤å•æŠ—è”åˆä¼ŠåŒ¹æœ¨å•æŠ—æ²»ç–—æœŸé—´ï¼Œè¡€æ¶²å‚æ•°ã€å…¨è¡€è½¬å½•ç»„è°±ä¸å…ç–«ç›¸å…³ä¸è‰¯äº‹ä»¶ä¹‹é—´çš„å…³è”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319387" target="_blank" rel="noopener noreferrer">GSE319387 ä¹³è…ºç™Œè¡€æ¸… tsRNA-Gly-5-0006ï¼šå·®å¼‚è¡¨è¾¾åŠå…¶å¯¹ç™Œç»†èƒç”Ÿç‰©å­¦çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319070" target="_blank" rel="noopener noreferrer">GSE319070 SMARCA4 é€šè¿‡ H3K27 ä¹™é…°åŒ–è°ƒæ§ PROX1 ä¿ƒè¿›å‰åˆ—è…ºç™Œç»†èƒçš„è°±ç³»å¯å¡‘æ€§å’Œæ©æ‰å¢èƒºè€è¯æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307936" target="_blank" rel="noopener noreferrer">GSE307936 PKM2 ä¹³é…¸åŒ–ä¿ƒè¿›ç»“ç›´è‚ ç™Œè¡€ç®¡ç”Ÿæˆæ‹Ÿæ€å’Œå¯¹è´ä¼å•æŠ—æ²»ç–—çš„è€è¯æ€§ï¼Œé€šè¿‡ä¿ƒè¿› FOSL1 è¶…çº§å¢å¼ºå­çš„å½¢æˆ [CUT&amp;Tag]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230908" target="_blank" rel="noopener noreferrer">GSE230908 å¯¹å…ç–«ç»„ç»‡å’Œå™¨å®˜çš„å•ç»†èƒåˆ†ææ­ç¤ºäº†é›„æ€§æ’æ²³çŒ´çš„å…ç–«è¡°è€ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306946" target="_blank" rel="noopener noreferrer">GSE306946 ç¼ºå¤± Norrin/Î²-catenin ä¿¡å·é€šè·¯ç»„åˆ†æˆ– KIF11 æˆ– PRDX1 çš„ HREC çš„ RNA-SEQ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305756" target="_blank" rel="noopener noreferrer">GSE305756 å°é¼ è§†ç½‘è†œè¡€ç®¡ç»†èƒå•ç»†èƒè½¬å½•ç»„åˆ†ææ­ç¤ºäº†å®¶æ—æ€§æ¸—å‡ºæ€§ç»ç’ƒä½“è§†ç½‘è†œç—…å˜çš„æœºåˆ¶ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304886" target="_blank" rel="noopener noreferrer">GSE304886 è‚ é“æµ†ç»†èƒæ ·æ ‘çªçŠ¶ç»†èƒä¼˜å…ˆäº§ç”Ÿå¹²æ‰°ç´ Î»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296138" target="_blank" rel="noopener noreferrer">GSE296138 å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚å¯¹äººæºåŒ–åµŒåˆå°é¼ æ¨¡å‹è‚¾è„çš„å½±å“ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312696" target="_blank" rel="noopener noreferrer">GSE312696 é›Œæ¿€ç´ å—ä½“Î±é€šè¿‡è°ƒèŠ‚VAT Tregs (oVAT)æ¥æŠµæŠ—è‚¥èƒ–å¼•èµ·çš„ä»£è°¢åŠŸèƒ½éšœç¢</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304776" target="_blank" rel="noopener noreferrer">GSE304776 LGR5âºå¹²ç»†èƒåœ¨è‚ ä¸Šçš®ç»†èƒçš„å†ç”Ÿå±‚çº§ä¸­ä¿æŒé¡¶ç«¯ä½ç½®ï¼Œæ— è®ºæ˜¯åœ¨ç¨³æ€è¿˜æ˜¯æŸä¼¤çŠ¶æ€ä¸‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303999" target="_blank" rel="noopener noreferrer">GSE303999 scRNA-seqæ­ç¤ºæ»‘è†œç»„ç»‡ä¸­ç«¯ç²’ç»†èƒçš„è½¬å½•è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295128" target="_blank" rel="noopener noreferrer">GSE295128 ATACseq å¯¹ giredestrant è€è¯çš„ ER+ ä¹³è…ºç™Œç»†èƒç³»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294200" target="_blank" rel="noopener noreferrer">GSE294200 é›Œæ¿€ç´ å—ä½“Î±é€šè¿‡è°ƒèŠ‚å†…è„è„‚è‚ªç»„ç»‡è°ƒèŠ‚å› å­ï¼ˆVAT Tregsï¼‰æ¥æŠµæŠ—è‚¥èƒ–å¼•èµ·çš„ä»£è°¢åŠŸèƒ½éšœç¢</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291529" target="_blank" rel="noopener noreferrer">GSE291529 åˆ©ç”¨å…¨åŸºå› ç»„ CRISPR ç­›é€‰é‰´å®šè°ƒæ§ PFOS ç»†èƒæ¯’æ€§ååº”çš„åŠŸèƒ½æ€§é—ä¼ æˆåˆ†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267725" target="_blank" rel="noopener noreferrer">GSE267725 æ ¸å—ä½“ ESRRA é€šè¿‡å¯¹è¶…çº§å¢å¼ºå­å’Œå¯åŠ¨å­çš„åŒé‡ä½œç”¨æ¥è°ƒèŠ‚åŸºå› è½¬å½•ç¨‹åºï¼Œä»è€Œä¿ƒè¿› ERÎ± é˜³æ€§ä¹³è…ºç™Œçš„å‘ç”Ÿå‘å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267724" target="_blank" rel="noopener noreferrer">GSE267724 æ ¸å—ä½“ ESRRA é€šè¿‡å¯¹è¶…çº§å¢å¼ºå­å’Œå¯åŠ¨å­çš„åŒé‡ä½œç”¨æ¥è°ƒèŠ‚åŸºå› è½¬å½•ç¨‹åºï¼Œä»è€Œä¿ƒè¿› ERÎ± é˜³æ€§ä¹³è…ºç™Œçš„å‘ç”Ÿã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313133" target="_blank" rel="noopener noreferrer">GSE313133 HE4 é€šè¿‡ IFN-Î³R-STAT3 è½´ä¸Šè°ƒå·¨å™¬ç»†èƒä¸Šçš„ PD-L1 è¡¨è¾¾æ¥è°ƒèŠ‚æŠ—ç™Œå…ç–«é€ƒé€¸ [L1MKK]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308759" target="_blank" rel="noopener noreferrer">GSE308759 C57BL/6å°é¼ ç¼ºè¡€/å†çŒæ³¨æŸä¼¤åçš„è½¬å½•ç»„å˜åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298300" target="_blank" rel="noopener noreferrer">GSE298300 HE4 é€šè¿‡ IFN-Î³R-STAT3 è½´ä¸Šè°ƒå·¨å™¬ç»†èƒä¸Š PD-L1 çš„è¡¨è¾¾ï¼Œä»è€Œè°ƒæ§æŠ—è‚¿ç˜¤å…ç–«é€ƒé€¸ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296417" target="_blank" rel="noopener noreferrer">GSE296417 CTCF åœ¨çº¢ç³»åˆ†åŒ–è¿‡ç¨‹ä¸­è°ƒèŠ‚ HBAD åŸºå› å¯åŠ¨å­çš„æŸ“è‰²è´¨å¯åŠæ€§ [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317352" target="_blank" rel="noopener noreferrer">GSE317352 æ—©æœŸè¾…åŠ©æŠ—PD-L1ç–—æ³•å¯æ”¹å–„å°é¼ è‚ºæ¯›éœ‰èŒç—…çš„é¢„åå¹¶é€†è½¬å…ç–«éº»ç—¹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312091" target="_blank" rel="noopener noreferrer">GSE312091 RNA-seq åˆ†æäº†ç» Nr4a1 æ¿€åŠ¨å‰‚ç»†èƒå­¢å­é…® B å¤„ç†çš„ SKG å°é¼ ä¸­ TCR åˆºæ¿€çš„ CD4âº T ç»†èƒã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290820" target="_blank" rel="noopener noreferrer">GSE290820 å·¥ç¨‹æ”¹é€ å›ºæœ‰æ— åºåŒº (IDR) ä»¥å¼•å¯¼åŸºå› ç»„å¯¼èˆª</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289561" target="_blank" rel="noopener noreferrer">GSE289561 Long-term chronic exposure of mice to sodium fluoride and a mixture of endocrine disruptors lead to easily observable tooth enamel and retina abnormalities underlying changes in hepatic metabolism</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286416" target="_blank" rel="noopener noreferrer">GSE286416 å¤šå°ºåº¦é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚å¿ƒè„æ¯’æ€§åˆ†ææ­ç¤ºæœºæ¢°æ•æ„Ÿæ€§ç¦»å­é€šé“ PIEZO1 å…·æœ‰å¿ƒè„ä¿æŠ¤ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126178" target="_blank" rel="noopener noreferrer">GSE126178 é“¬æš´éœ²çš„æ—¶é—´è¿›ç¨‹ï¼ˆRNA-Seqï¼‰</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-14 21:43</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>